Rosaramicin and tetracycline treatment in Chlamydia trachomatis-positive and -negative nongonococcal urethritis.
Rosaramicin, a new macrolide antibiotic, is active in vitro against Chlamydia trachomatis and Ureaplasma urealyticum. Its efficacy in the treatment of uncomplicated nongonococcal urethritis was evaluated in 78 men. There were two parallel groups, one receiving rosaramicin and the other receiving tetracycline (dosage of either drug, 250 mg four times daily for seven days); all data were evaluated blindly. The follow-up period was six weeks. C. trachomatis was eliminated from all of 21 patients receiving rosaramicin and from 25 of 26 patients receiving tetracycline. C. trachomatis-negative patients responded clinically to both treatments. The results suggest that these two antibiotics yield similar clinical outcomes in the treatment of nongonococcal urethritis in adult men.
D002690:Chlamydia Infections / Q000188:drug therapy* / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D004334:Drug Administration Schedule; D006801:Humans; D007933:Leucomycins / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D013607:Tablets; D013752:Tetracycline / Q000009:adverse effects / Q000627:therapeutic use*; D014526:Urethritis / Q000188:drug therapy* / Q000382:microbiology
D007933:Leucomycins; D013607:Tablets; D013752:Tetracycline